© 2016 SEICAP Background Chronic spontaneous urticaria (CSU) is a frequent clinical entity that often presents a diagnostic and therapeutic challenge. Objective To explore the degree of agreement that exists among the experts caring for patients with CSU diagnosis, evaluation, and management. Methods An online survey was conducted to explore the opinions of experts in CSU, address controversial issues, and provide recommendations regarding its definition, natural history, diagnosis, and treatment. A modified Delphi method was used for the consensus. Results The questionnaire was answered by 68 experts (dermatologists, allergologists, and primary care physicians). A consensus was reached on 54 of the 65 items posed (96.4%). The experts concluded that CSU is a difficult-to-control disease of unpredictable evolution. Diagnostic tests should be limited and based on clinical history and should not be indiscriminate. Autoinflammatory syndromes and urticarial vasculitis must be ruled out in the differential diagnosis. A cutaneous biopsy is only recommended when wheals last more than 24 h, to rule out urticarial vasculitis. The use of specific scales to assess the severity of the disease and the quality of life is recommended. In patients with severe and resistant CSU, second-generation H1-antihistamines could be used at doses up to four times the standard dose before giving second-line treatments. Omalizumab is a safe and effective treatment for CSU that is refractory to H1-antihistamines treatment. In general, diagnosis and treatment recommendations given for adults could be extrapolated to children. Conclusions This work offers consensus recommendations that may be useful in the management of CSU.
- Delphi technique
Giménez-Arnau, A., Ferrer, M., Bartra, J., Jáuregui, I., Labrador-Horrillo, M., Frutos, J. O. D., Silvestre, J. F., Sastre, J., Velasco, M., & Valero, A. (2017). Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements. Allergologia et Immunopathologia, 45(2), 134-144. https://doi.org/10.1016/j.aller.2016.06.007